Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole augmentation in treatment-resistant depression
NCT00276978Phase 3Withdrawn
- Sponsor
- University Hospital Freiburg
- Start
- Jun 2005
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of aripiprazole in major depressive disorder (MDD), sponsored by University Hospital Freiburg. Primary endpoint: Response Rate (HAM-D) at 4 weeks. Planned start Jun 2005; status: withdrawn.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00276978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276978.